INBP Integrated BioPharma, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
21:13
Jan 01
Jan 01
Deep value below liquidation value; acquisition by Celsius founders likely
The author argues INBP is deeply undervalued at 0.1x revenue, 2.4x EV/EBITDA, and below liquidation value, with inventory alone exceeding market cap. He expects the billionaire Celsius founders who own 43% to eventually acquire the company at a significant premium, potentially around $1/share versus the low $0.30s. The main stated risk is customer concentration with Life Extension and Herbalife representing the majority of revenue.
HIGH
About INBP Investor Commentary
Across the available history and selected sources, Buzzberg tracks INBP (Integrated BioPharma, Inc.) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: u/Holla_Ackbar.